Axelsson M - Search Results

1

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.

Öhrfelt A, Axelsson M, Malmeström C, Novakova L, Heslegrave A, Blennow K, Lycke J, Zetterberg H. Öhrfelt A, et al. Among authors: axelsson m. Mult Scler. 2016 Oct;22(12):1587-1595. doi: 10.1177/1352458515624558. Epub 2016 Jan 11. Mult Scler. 2016. PMID: 26754805

2

MS risk genes are transcriptionally regulated in CSF leukocytes at relapse.

Jernås M, Malmeström C, Axelsson M, Olsson C, Nookaew I, Wadenvik H, Zetterberg H, Blennow K, Lycke J, Rudemo M, Olsson B. Jernås M, et al. Among authors: axelsson m. Mult Scler. 2013 Apr;19(4):403-10. doi: 10.1177/1352458512455466. Epub 2012 Aug 20. Mult Scler. 2013. PMID: 22907940

3

Serum levels of LIGHT in MS.

Malmeström C, Gillett A, Jernås M, Khademi M, Axelsson M, Kockum I, Mattsson N, Zetterberg H, Blennow K, Alfredsson L, Wadenvik H, Lycke J, Olsson T, Olsson B. Malmeström C, et al. Among authors: axelsson m. Mult Scler. 2013 Jun;19(7):871-6. doi: 10.1177/1352458512463766. Epub 2012 Oct 4. Mult Scler. 2013. PMID: 23037546

4

Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.

Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, Malmeström C, Lycke J, Blennow K, Zetterberg H, Mattsson N. Augutis K, et al. Among authors: axelsson m. Mult Scler. 2013 Apr;19(5):543-52. doi: 10.1177/1352458512460603. Epub 2012 Oct 15. Mult Scler. 2013. PMID: 23069872

5

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A. Axelsson M, et al. Mult Scler. 2014 Jan;20(1):43-50. doi: 10.1177/1352458513490544. Epub 2013 May 23. Mult Scler. 2014. PMID: 23702432

6

The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.

Axelsson M, Mattsson N, Malmeström C, Zetterberg H, Lycke J. Axelsson M, et al. J Neuroimmunol. 2013 Nov 15;264(1-2):100-5. doi: 10.1016/j.jneuroim.2013.09.003. Epub 2013 Sep 18. J Neuroimmunol. 2013. PMID: 24125567

7

CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.

Malmeström C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B. Malmeström C, et al. Among authors: axelsson m. J Neuroimmunol. 2014 Apr 15;269(1-2):87-9. doi: 10.1016/j.jneuroim.2014.02.004. Epub 2014 Feb 13. J Neuroimmunol. 2014. PMID: 24582001

8

Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.

Novakova L, Axelsson M, Malmeström C, Zetterberg H, Björkhem I, Karrenbauer VD, Lycke J. Novakova L, et al. Among authors: axelsson m. J Neurol Sci. 2015 Nov 15;358(1-2):201-6. doi: 10.1016/j.jns.2015.08.1537. Epub 2015 Aug 29. J Neurol Sci. 2015. PMID: 26342940

9

YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.

Burman J, Raininko R, Blennow K, Zetterberg H, Axelsson M, Malmeström C. Burman J, et al. Among authors: axelsson m. J Neuroimmunol. 2016 Mar 15;292:52-7. doi: 10.1016/j.jneuroim.2016.01.013. Epub 2016 Jan 22. J Neuroimmunol. 2016. PMID: 26943959 Free article.

10

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J. Novakova L, et al. Among authors: axelsson m. Mult Scler. 2017 Jan;23(1):62-71. doi: 10.1177/1352458516639384. Epub 2016 Jul 11. Mult Scler. 2017. PMID: 27003946

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

376 results

Search Page